Myron Liebhaber, MD
Allergy & Immunology · Santa Barbara, CANPI 1346253390
Payments from drug & device makers
Across 994 payments — averaging $368.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$111K
- Takeda Pharmaceuticals U.S.A., Inc.$67K
- Pharming Healthcare, Inc.$57K
- Phadia US Inc.$39K
- Grifols USA, LLC$22K
- CSL Behring$18K
- plus $52K from 29 others
What the payments were for
- Consulting fees$56,13316%
- Speaking & faculty fees$238,81167%
- Travel & lodging$39,56111%
- Food & beverage$19,3375%
- Education$2510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 152 | $110,678 |
| Takeda Pharmaceuticals U.S.A., Inc. | 131 | $67,347 |
| Pharming Healthcare, Inc. | 96 | $57,482 |
| Phadia US Inc. | 45 | $38,740 |
| Grifols USA, LLC | 59 | $21,787 |
| CSL Behring | 66 | $18,233 |
| Boehringer Ingelheim | 48 | $16,239 |
| Octapharma USA, Inc. | 9 | $11,799 |
| Pfizer | 47 | $6,763 |
| Biocryst Pharmaceuticals, Inc. | 9 | $4,935 |
| Genentech USA, Inc. | 12 | $2,078 |
| Biocryst US Sales Co., LLC | 23 | $1,812 |
| Blueprint Medicines Corporation | 2 | $1,805 |
| GSK | 103 | $1,620 |
| AstraZeneca | 40 | $862 |
| Sanofi | 30 | $858 |
| Regeneron Healthcare Solutions, Inc. | 28 | $670 |
| Novartis | 20 | $355 |
| Optinose US, Inc. | 14 | $316 |
| Amgen(2 entities) | 10 | $250 |
| Incyte Corporation | 11 | $244 |
| Alk-abello, Inc | 10 | $229 |
| Ionis Pharmaceuticals, Inc. | 4 | $101 |
| Teva Pharmaceuticals USA, Inc. | 5 | $93 |
| Sobi, Inc | 1 | $92 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $73 |
| Hikma Pharmaceuticals USA | 3 | $69 |
| Greer Laboratories, Inc. | 2 | $65 |
| Kaleo, Inc. | 2 | $42 |
| Bio Products Laboratory USA, Inc. | 2 | $37 |
| Cycle Pharmaceuticals Inc | 1 | $34 |
| Organon | 2 | $32 |
| Covis Pharma GmbH | 2 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$365,804 in reported general payments places this provider in the 90th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 23 | $1,156,260 |
| XembifyImmune Globulin,gamma(Igg)klhw | 26 | $196,734 |
| CutaquigImmun Glob G(Igg)-Hipp/Maltose | 15 | $104,076 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $101,042 |
| IcatibantIcatibant Acetate | 22 | $78,081 |
| Dupixent PenDupilumab | 11 | $40,911 |
| XolairOmalizumab | 12 | $34,801 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $33,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $28,533 |
| Spiriva RespimatTiotropium Bromide | 30 | $21,789 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $11,242 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 67 | $8,997 |
| Wixela InhubFluticasone Propion/Salmeterol | 96 | $8,746 |
| Fluticasone Propionate HfaFluticasone Propionate | 29 | $8,177 |
| Arnuity ElliptaFluticasone Furoate | 26 | $6,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $67,347 | $1,156,26023 claims |
| Grifols USA, LLCXembify | $21,787 | $196,73426 claims |
| Octapharma USA, Inc.Cutaquig | $11,799 | $104,07615 claims |
| CSL BehringHizentra | $18,233 | $101,04212 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $1,620 | $68,546144 claims |
| Boehringer IngelheimSpiriva Respimat | $16,239 | $21,78930 claims |
| AstraZenecaSymbicort | $862 | $11,24242 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Proair Respiclick | $93 | $5,73829 claims |
| Hikma Pharmaceuticals USAEpinephrine | $69 | $2,83220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Santa Barbara
- Kenneth KimLong Beach$18.5M
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Tonny TanusBakersfield$4.5M
- Raffi TachdjianSanta Monica$4.2M
- Vinay MehtaLaguna Niguel$3.3M
- Alan GoldsobelSan Jose$3.3M
- Steven WeinsteinHuntington Beach$3M
- James WolfeSan Jose$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.